Abstract
More than 11% of the global cancer incidence in females is due to human papillomavirus (HPV) infections, with HPV genotype 16 the most prevalent viral type to infect the cervix. HPV vaccines currently target HPV 16 genes E6 and E7, constitutively expressed in cervical cancer cells; and L1 and L2, HPV surface antigens. Successful vaccination to combat cervical cancer requires two vaccine strategies: an antiviral vaccine to prevent viral infection (prophylactic vaccination), and an anticancer vaccine to eliminate both virally-infected cells and virally-induced tumor cells (therapeutic vaccination).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 204-209 |
| Number of pages | 6 |
| Journal | CME Journal of Gynecologic Oncology |
| Volume | 9 |
| Issue number | 3 PART 3 |
| State | Published - Dec 1 2004 |
Keywords
- Anticancer vaccines
- Antiviral vaccines
- Cervical cancer
- HPV vaccines
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology